![Cécile Cluzel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cécile Cluzel
Directeur/Membre du Conseil chez
OSE IMMUNOTHERAPEUTICS
Profil
Cécile Nguyen-Cluzel is currently an Independent Director at OSE Immunotherapeutics SA since 2024, a Partner at Latour Capital Management SAS starting in 2025, and a Senior Advisor at Apposite Capital LLP since 2024.
Formerly, Ms. Nguyen-Cluzel was a Partner at MBO+ SAS from 2008 to 2023.
Education includes a graduate degree from Université Paris Dauphine-PSL conferred in 1994.
Postes actifs de Cécile Cluzel
| Sociétés | Poste | Début |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Directeur/Membre du Conseil | 19/06/2024 |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital invests in companies located in the United Kingdom and European with revenues of up to EUR 100 million. The firm focuses on the technology sector. It provides financing for MBOs, buy-ins and growth capital requirements. It also acquires minority interest. | Private Equity Investor | 01/01/2024 |
Latour Capital Management SAS
 Latour Capital Management SAS Investment ManagersFinance Latour Capital is an active manager which provides both equity and debt financing in small and medium-sized companies located in France. The firm targets companies operating in the business services sector with an enterprise value between EUR 50 million and EUR 300 million. It invests through buyout transactions, and looks to take both minority and majority stake positions in its investments. | Private Equity Investor | 01/09/2025 |
Anciens postes connus de Cécile Cluzel
| Sociétés | Poste | Fin |
|---|---|---|
MBO+ SAS
 MBO+ SAS Investment ManagersFinance MBO+ SAS invests in lower mid-cap companies located in France with an enterprise value of EUR 20 - 200 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing in the form of equity and quasi-equity for LBO, shareholder liquidity, acquisitions and buyout capital transactions with an investment size of EUR 10 - 45 million. | Private Equity Investor | 30/06/2023 |
Formation de Cécile Cluzel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
69
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
MBO+ SAS
MBO+ SAS Investment ManagersFinance MBO+ SAS invests in lower mid-cap companies located in France with an enterprise value of EUR 20 - 200 million. The firm targets companies operating across a broad range of sectors and industries. It provides financing in the form of equity and quasi-equity for LBO, shareholder liquidity, acquisitions and buyout capital transactions with an investment size of EUR 10 - 45 million. | Finance |
Université Paris Dauphine-PSL
 Université Paris Dauphine-PSL Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Apposite Capital LLP
Apposite Capital LLP Investment ManagersFinance Apposite Capital invests in companies located in the United Kingdom and European with revenues of up to EUR 100 million. The firm focuses on the technology sector. It provides financing for MBOs, buy-ins and growth capital requirements. It also acquires minority interest. | Finance |
Latour Capital Management SAS
Latour Capital Management SAS Investment ManagersFinance Latour Capital is an active manager which provides both equity and debt financing in small and medium-sized companies located in France. The firm targets companies operating in the business services sector with an enterprise value between EUR 50 million and EUR 300 million. It invests through buyout transactions, and looks to take both minority and majority stake positions in its investments. | Finance |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
Choisissez Zonebourse 
